Na Cocer Peptides 
25 mau lā aku nei.
Mālama ka ʻōnaehana immune i ka homeostasis kino ma o kahi ʻoihana paʻakikī o nā cell a me nā molekala, ʻoiai ʻo ka dysregulated immune responses hiki ke alakaʻi i nā maʻi, ʻeha mau, a i ʻole nā maʻi autoimmune. ʻO ke kumu o ka hoʻoponopono immune, ka hoʻohaʻahaʻa ʻana i ka mumū, a me ka adjuvant therapy no nā maʻi autoimmune aia i ka hana pololei i ka hoʻoulu ʻana o ka cell immune, nā ala hōʻailona inflammatory, a me nā mīkini pale pale. E like me nā molekala bioactive, nā mea peptide, me kā lākou kikoʻī kikoʻī kiʻekiʻe a me ka biocompatibility, hiki ke hoʻololi pono i nā hana cell immune, kaohi i ka transduction hōʻailona pro-inflammatory, a hoʻololi hou i ka microenvironment immune, e hāʻawi ana i nā hopena hou no ka mālama ʻana i nā maʻi maʻi, nā maʻi autoimmune, a me nā kūlana pili i ka mumū.
Kiʻi 1 He Papahana Nui no ka wehewehe ʻana i ke kumu o ka maʻi ʻeha. Source: Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer (2006).
Nā ʻāpana noi kumu
1. Hoʻoponopono i ka Immune: Reshaping Immune Cell Response Equilibrium
Loaʻa i nā mea peptide ka hoʻoponopono bidirectional o ka ikaika a me ke kuhikuhi o nā pane pale ma o ka hoʻololi ʻana i ka ʻokoʻa, hoʻonui, a me nā hana hopena o nā cell immune.
Hoʻoponopono i nā ʻāpana T cell
ʻO nā peptide e like me Thymosin Alpha-1, e like me nā peptides bioactive i loaʻa mai ka thymus, e hoʻolalelale i ka maturation o nā precursors cell T i loko o nā pūnae T hana, e hoʻonui ai i nā hopena synergistic ma waena o CD4⁺ helper T cell a me CD8⁺ cytotoxic T cell. Ma ka hoʻoulu ʻana i nā ala hōʻailona intracellular, hoʻomaikaʻi kēia mau peptides i ka hiki ke ʻike antigen o nā cell T, hoʻoikaika i ka huna ʻana o ka cytokine, a hoʻomaikaʻi i ka pono o ke kino i ka hoʻomaʻemaʻe ʻana i nā pathogens a me nā cell abnormal, e kūpono ana iā lākou no ka pale ʻana i ka maʻi i nā poʻe immunocompromised a me ka adjuvant cancer therapy.
Hoʻoponopono i nā peptides e hoʻoulu ai i ka cell T
Hiki i nā peptides pōkole i loaʻa mai nā protein kanaka maoli ke hoʻoikaika i ka hoʻonui ʻana o nā pūnaewele T regulatory (Tregs) a kāohi i nā cell T effector overactivated. Mālama kēia mau Tregs i ka pale ʻana i ka pale ʻana i ka hoʻololi ʻana o ke kino a me nā maʻi autoimmune ma o ka hūnā ʻana i nā cytokine inhibitory e hoʻopau i ka hoʻoulu ʻana o ka immune.
Hoʻonui i nā hana o nā cell immune innate
ʻO nā peptides antimicrobial (AMPs) e like me LL37 e hōʻike ana i nā hana ʻelua o ka hana antimicrobial a me ka hoʻoponopono pale. Hana pololei lākou i nā membrane pathogen no nā hopena bactericidal a hoʻoulu i ka maturation cell dendritic, e hoʻolaha ana i ka hōʻike antigen a me ka hoʻoulu ʻana o T cell, no laila ke pāʻani nei i kahi kuleana koʻikoʻi i ka pale ʻana i nā pale kino e like me ka ʻili a me ka mucosa.
Kiʻi 2 ʻO ka hana hoʻoponopono o nā AMP ma nā macrophages. Source: Ka Haʻawina o Antimicrobial Peptides i ka Immune Cell Function: A Review of Recent Advances (2023).
2. Hoʻohaʻahaʻa i ka Inflammation: Multi-pathway Blockade of Inflammatory Cascades
Ke kuhikuhi nei i nā kī kī o ka pane inflammatory, hoʻohana nā mea peptide i nā hopena ma ke kāohi ʻana i nā hōʻailona pro-inflammatory, hoʻolaha i ka hana anti-inflammatory mediator, a me ka hoʻoponopono ʻana i ka microenvironment tissue.
ʻO ka pāpā waena o ke ala NF-κB
Hoʻopili nā peptides palekana gastrointestinal e like me BPC-157 i ke ala hōʻailona nuklea κB (NF-κB), e kāohi ana i ka transcription a me ka hoʻokuʻu ʻana o nā cytokine pro-inflammatory a me ka hoʻohaʻahaʻa ʻana i ka edema inflammatory tissue kūloko. Hoʻohui ʻia, hoʻolaha lākou i ka hōʻike ʻana o nā genes pili i ka mucosal, e hoʻolalelale ana i ka ho'ōla ʻana i nā ʻiʻo i hōʻino ʻia, e hōʻike ana i nā hopena anti-inflammatory a me ka reparative i nā maʻi e like me ka maʻi ʻeha a me nā maʻi ʻeha.
Nā peptides i loaʻa i ke kininogen
Hoʻoponopono nā peptide e like me KPV i ka hana neutrophil a me ka ʻōlelo mole adhesion, e hōʻemi ana i ka infiltration o nā cell inflammatory ma nā wahi ʻeha, e hoʻemi ana i ka pōʻino oxidative stress, a me ka hoʻomaikaʻi ʻana i ka microenvironment kūloko. Ua kūpono kēia mau waiwai no ka mālama ʻana i nā maʻi e pili ana i ka mumū e like me ka ischemia-reperfusion injury a me ka maʻi ʻeha wāwae maʻi.
Hoʻoponopono synergistic o ka mitochondria a me ke kaumaha oxidative
ʻO nā peptides i hoʻopaʻa ʻia ʻo Mitochondria e like me SS-31 i hoʻopaʻa ʻia i ka mitochondrial membrane structures, e pale ana i ka mitochondrial functional integrity, e hōʻemi ana i ka excessive reactive oxygen species (ROS) hana, a me ke kāohi ʻana i ka hōʻailona hōʻailona apoptosis. Hoʻopau kēia i ka pōʻino o ke koʻikoʻi o ka oxidative stress-induced a hāʻawi i ka pale o ke kino i ka ʻeha cardiovascular a me nā maʻi neurodegenerative.
3. ʻO ka Adjuvant Therapy no nā maʻi autoimmune: hana hou i ka microenvironment hoʻomanawanui.
Ke manaʻo nei i ka hoʻouka hewa ʻana o ka ʻōnaehana pale i nā ʻāpana ponoʻī i nā maʻi autoimmune, hoʻohana nā mea peptide i nā hopena therapeutic adjuvant ma o ka hoʻoponopono ʻana i ka ʻike a me nā hana effector.
Antigen-specific immune tolerance induction
ʻO nā peptides pōkole i loaʻa mai nā epitopes antigen ponoʻī e hoʻopaʻa i nā molekala ma ka ʻili o nā pūnaewele hōʻike antigen, e hoʻoulu ai i ka hoʻomanawanui ʻana o nā cell immune i nā antigens ponoʻī. Hoʻemi kēia i ka hana ʻana o nā autoantibodies a me ka hoʻouka ʻana o ka ʻiʻo e nā cell T effector, e hāʻawi ana i kahi hoʻolālā hoʻolālā i manaʻo ʻia no nā maʻi e like me ka rheumatoid arthritis a me systemic lupus erythematosus.
Hoʻoponopono kaulike o ka pūnaewele cytokine
Hoʻololi kekahi mau peptides i ka hoʻokaʻawale ʻana o nā subsets cell Th1 / Th2 / Th17 a me nā ʻōnaehana huna cytokine, ke kāohi nei i ka hōʻike nui ʻana o nā mea pro-inflammatory a me ka hoʻoikaika ʻana i ka hana o nā cytokine anti-inflammatory. Hoʻopau kēia i nā pane inflammatory mau i nā maʻi autoimmune a hoʻomaikaʻi i ka pōʻino o ke kino.
Ka hopena
ʻO nā mea peptide i ke kahua o ka pale a me ka anti-inflammation ua lilo i mau mea hana koʻikoʻi no ka hoʻoponopono ʻana i ka pale pale pale a me ka kāohi ʻana i nā pane ʻeha ma muli o kā lākou kikoʻī kikoʻī kikoʻī a me nā hopena synergistic multi-mechanistic. Ma ke komo ʻana i ka hoʻokaʻawale ʻana o ka cell T, nā ala hōʻailona inflammatory, a me nā ʻano hana hoʻomanawanui, ʻaʻole kēia mau mea e hoʻomaikaʻi wale i ka pale o ke kino i nā pathogens akā ke keʻakeʻa nei hoʻi i ka pōʻino o ka ʻiʻo i hoʻokumu ʻia e ka nui o nā pane kūlohelohe, e hāʻawi ana i nā ʻano ʻokoʻa no ka mālama ʻana i nā maʻi maʻi, nā maʻi autoimmune, a me ka mumū mau.
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a maʻi paha. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.
